For fully automated and repeated row-by-row exposure of 12-, 24- and 96-well sized cell culture inserts. Testing of up to 12 dose ranges in one experiment.

The VITROCELL® Cloud Alpha MOVE is our newest innovation and presents another great leap forward in fully automated exposure of cell cultures. It is the ideal device to obtain a dose-response relationship in one experiment.

VITROCELL® Cloud Alpha MOVE  (PDF)

Read more

Aerosol exposure for breathing AX Lung-on-Chip

The VITROCELL® Cloud Alpha AX12 is our newest innovation in the Cloud family and presents a great leap forward in automated exposure of cell cultures with breathing function. It combines highly efficient testing with ease of use. The development is based on the well-known and frequently published VITROCELL® Cloud formats (6-, 12-, 24- and 96-well).
Its functionality enables fully automated processes with an all-in-one control unit. Everyday experiments at the Air/Liquid Interface have never been easier.

It is suitable for the nebulization of solutions and suspensions. Fields of application are, but are not limited to, screening of inhaled drugs and toxicity testing of inhaled substances such as chemicals, nanoparticles and airborne pathogens.

VITROCELL® Cloud Alpha AX 12  (PDF)

Read more

Increase of nebulizations and evacuation of residual gaseous compounds

A typical Cloud exposure allows 3 consecutive nebulizations. The PowerVent option enables an increase of the dose by adding further nebulizations. After each nebulization the humidity is removed by a short venting period before starting the new one. The venting function can be edited in the software. The PowerVent unit is delivered ready-to-use with an integrated vacuum pump.

VITROCELL® Cloud Alpha PowerVent  (PDF)

Read more

For liquid droplet sizes 9 – 12 μm with diffusor

Certain chemicals or formulations, for example nasal sprays, often have larger particle sizes than the mesh size of standard nebulizers (4.0 – 6.0 μm). The VITROCELL Cloud Advanced Nebulizer is enlarging the application areas of Cloud Exposure Systems. This special type offers the possibility to produce an aerosol containing particles in the range of 9.0 – 12.0 μm.
Our patented Cloud diffusor ensures a homogeneous distribution of even the larger droplet sizes in the Cloud Exposure Chamber. To avoid effects from larger droplet formations it has an integrated drain channel.

VITROCELL® Cloud Advanced Nebulizer  (PDF)

Read more

https://doi.org/10.1016/j.bbrep.2021.101187

David Bovard ^b, Marco van der Toorn ^b, Walter K. Schlage ^a, Samuel Constant ^c, Kasper Renggli ^b, Manuel C. Peitsch ^b, Julia Hoeng ^b,
^a Biology Consultant, Max-Baermann-Str. 21, 51429, Bergisch Gladbach, Germany
^b PMI R&D, Philip Morris Products S.A, Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland
^c Epithelix Sarl, 18 Chemin des Aulx, Plan-les-Ouates, 1228, Geneva, Switzerland

This study successfully demonstrates the exposure of human bronchial epithelial cultures to defined doses of nebulized Iota-carrageenan which were reproducibly generated and administered using the VITROCELL Cloud 12 system. 
The aim of this study was to further investigate the efficacy and safety of IC treatment on SARS-CoV-2 infection by using advanced in vitro models of human respiratory epithelium, the primary target and entry port of SARS-CoV-2. The experimental models were 3D cultures of reconstituted bronchial and nasal epithelia, representing the surface of the human upper respiratory tract. This apical exposure of reconstructed epithelia more closely mimics real-life exposure conditions and the absence of toxicity or any functional or structural impairment of the bronchial mucociliary epithelium demonstrates that topical treatment with nebulized IC is well tolerated at the effective concentrations. 

Read more